Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 10/20 | 0.52 |
| ▸ | NR2E3 | Q9Y5X4 | 5/20 | 0.48 |
| ▸ | PRSS12 | P56730 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1136423 | 0.88 | CHEK2 (0.52) | CHEK2NR2E3KDM4EALDH1A1MAPT | |
| SCHEMBL1136430 | 0.88 | NR2E3 (0.47) | NR2E3KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL1136390 | 0.87 | NR2E3 (0.59) | NR2E3PRSS12KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL1136397 | 0.87 | NR2E3 (0.61) | NR2E3KDM4EMAPTSMN1; SMN2KDR | |
| SCHEMBL4472721 | 0.87 | NR2E3 (0.59) | NR2E3KDR | |
| SCHEMBL4600467 | 0.85 | NR2E3 (0.58) | CHEK2NR2E3PRSS12KDM4EALDH1A1 | |
| SCHEMBL1136351 | 0.84 | NR2E3 (0.55) | NR2E3KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL1136438 | 0.83 | PPARG (0.60) | ALDH1A1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL4487422 | 0.81 | MMP2 (0.58) | CHEK2NR2E3KDM4EALDH1A1MAPT | |
| SCHEMBL4466225 | 0.80 | NR2E3 (0.57) | NR2E3KDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919910-B1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | claimed |
| US-20090227578-A1 | Azabenzimidazole Derivatives, Their Manufacture and Use as Anti-Cancer Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | claimed |
| EP-1919910-A1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | F. Hoffmann-la Roche AG (CH) | 2008-05-14 | — | — | EP | claimed |
| WO-2007017143-A1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | claimed |
| US-20090227578-A1 | Azabenzimidazole Derivatives, Their Manufacture and Use as Anti-Cancer Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | disclosed |
| EP-1919910-A1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | F. Hoffmann-la Roche AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007017143-A1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227578-A1 | Azabenzimidazole Derivatives, Their Manufacture and Use as Anti-Cancer Agents | AZI2, CDKN1A, CCNI | CHEK2 1302/4885NR2E3 2691/4885PRSS12 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.